Next Article in Journal
Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet
Next Article in Special Issue
The Immunomodulatory and Neuroprotective Effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): A Model of Multiple Sclerosis (MS)
Previous Article in Journal
Genetic Diversity of Pinus nigra Arn. Populations in Southern Spain and Northern Morocco Revealed By Inter-Simple Sequence Repeat Profiles
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2012, 13(5), 5659-5673; doi:10.3390/ijms13055659

Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study

1
Buffalo Neuroimaging Analysis Center, State University of New York, Buffalo, NY 14203, USA
2
The Jacobs Neurological Institute, Department of Neurology, University at Buffalo, State University of New York, Buffalo, NY 14203, USA
*
Author to whom correspondence should be addressed.
Received: 22 March 2012 / Revised: 23 April 2012 / Accepted: 3 May 2012 / Published: 10 May 2012
(This article belongs to the Special Issue Recent Advances in the Research of Multiple Sclerosis)
View Full-Text   |   Download PDF [242 KB, uploaded 19 June 2014]   |  

Abstract

This study explored the effect of glatiramer acetate (GA, 20 mg) on lesion activity using the 1.5 T standard MRI protocol (single dose gadolinium [Gd] and 5-min delay) or optimized 3 T protocol (triple dose of Gd, 20-min delay and application of an off-resonance saturated magnetization transfer pulse). A 15-month, phase IV, open-label, single-blinded, prospective, observational study included 12 patients with relapsing-remitting multiple sclerosis who underwent serial MRI scans (Days −45, −20, 0; the minus ign indicates the number of days before GA treatment; and on Days 30, 60, 90, 120, 150, 180, 270 and 360 during GA treatment) on 1.5 T and 3 T protocols. Cumulative number and volume of Gd enhancing (Gd-E) and T2 lesions were calculated. At Days −45 and 0, there were higher number (p < 0.01) and volume (p < 0.05) of Gd-E lesions on 3 T optimized compared to 1.5 T standard protocol. However, at 180 and 360 days of the study, no significant differences in total and cumulative number of new Gd-E and T 2 lesions were found between the two protocols. Compared to pre-treatment period, at Days 180 and 360 a significantly greater decrease in the cumulative number of Gd-E lesions (p = 0.03 and 0.021, respectively) was found using the 3 T vs. the 1.5 T protocol (p = NS for both time points). This MRI mechanistic study suggests that GA may exert a greater effect on decreasing lesion activity as measured on 3 T optimized compared to 1.5 T standard protocol. View Full-Text
Keywords: glatiramer acetate; gadolinium-enhancing lesions; magnetic resonance imaging; 1.5 T; 3 T; T2 lesions; pilot trial glatiramer acetate; gadolinium-enhancing lesions; magnetic resonance imaging; 1.5 T; 3 T; T2 lesions; pilot trial
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zivadinov, R.; Hojnacki, D.; Hussein, S.; Bergsland, N.; Carl, E.; Durfee, J.; Dwyer, M.G.; Kennedy, C.; Weinstock-Guttman, B. Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. Int. J. Mol. Sci. 2012, 13, 5659-5673.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top